{"id":"NCT00566501","sponsor":"Eisai Inc.","briefTitle":"Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's Disease","officialTitle":"Open-Label Extension Study of 23 mg Donepezil SR in Patients With Moderate to Severe Alzheimer's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-12-14","primaryCompletion":"2010-04-01","completion":"2010-04-01","firstPosted":"2007-12-03","resultsPosted":"2012-06-19","lastUpdate":"2021-11-17"},"enrollment":915,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Alzheimer's Disease"],"interventions":[{"type":"DRUG","name":"Donepezil","otherNames":["Aricept"]}],"arms":[{"label":"Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)","type":"EXPERIMENTAL"},{"label":"Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety and efficacy of long-term administration of 23 milligram (mg) donepezil sustained release (SR) in participants with moderate to severe Alzheimer's disease. Participants who complete study E2020-G000-326 (NCT00478205) with no ongoing serious adverse events (SAEs) and no serious adverse drug reactions will be eligible to enter the open-label extension study.","primaryOutcome":{"measure":"Number of Participants With Adverse Events (AEs)","timeFrame":"From the enrollment of the study up to 30 days after last dose of the study drug (up to 2 years 3 months)","effectByArm":[{"arm":"Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)","deltaMin":416,"sd":null},{"arm":"Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)","deltaMin":259,"sd":null}],"pValues":[]},"eligibility":{"minAge":"45 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":80,"n":570},"commonTop":["Weight decreased","Fall","Agitation","Urinary tract infection","Aggression"]}}